Imaging Immune Activation in COVID-19

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Covid19SARS-CoV Infection
Interventions
DRUG

[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)

\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.

Trial Locations (1)

94110

RECRUITING

University of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

lead

CellSight Technologies, Inc.

INDUSTRY

NCT04815096 - Imaging Immune Activation in COVID-19 | Biotech Hunter | Biotech Hunter